Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Development of GLP-compliant Neutralizing Antibody (NAb) Assays for Monoclonal Antibody Therapeutics

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Development of GLP-compliant Neutralizing Antibody (NAb) Assays for Monoclonal Antibody Therapeutics

Development of GxP-Compliant Neutralizing Antibody (NAb) Assays for Monoclonal Antibody Therapeutics

CELL & GENE | RNA | BIOLOGICS

Executive Summary

A robust, GxP-compliant neutralizing antibody (NAb) assay is a required component for the regulatory submission of any monoclonal antibody therapeutic. These assays directly measure the functional impact of anti-drug antibodies (ADAs) on drug efficacy, providing data that informs clinical safety and dosing strategies. Franklin Biolabs develops and validates highly specific, drug-tolerant NAb assays tailored to your therapeutic’s mechanism of action, leveraging our deep expertise in cell-based and non-cell-based formats to support your program from discovery through post-market analysis.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

Frequently Asked Questions (FAQ)

    What defines a GxP-compliant NAb assay?

    A GxP-compliant NAb assay is a functional bioassay developed, qualified, and validated according to Good Laboratory Practice (GLP), Good Clinical Practice (GCP), or Good Manufacturing Practice (GMP) standards, depending on the development stage. Compliance ensures data integrity, reproducibility, and acceptability by regulatory agencies like the FDA and EMA for IND, BLA, and MAA submissions.

    What is the primary difference between a cell-based and a ligand-binding NAb assay?

    A cell-based assay measures the neutralizing capacity of antibodies by observing a direct biological effect on a responsive cell line (e.g., inhibition of proliferation, apoptosis, or reporter gene expression). A competitive ligand-binding assay (LBA) infers neutralization by measuring the ability of ADAs to inhibit the binding of the drug to its target ligand or receptor in a plate-based format. Cell-based assays are generally considered more reflective of the in vivo mechanism of action.

    How do you mitigate drug and target interference in a NAb assay?

    We employ several strategies, including acid dissociation to disrupt drug-ADA complexes, solid-phase extraction with acid dissociation (SPEAD), and affinity capture elution (ACE) methods. Assay design also incorporates steps to minimize interference from soluble targets or receptors present in study samples, ensuring the specific detection of functionally relevant NAbs.

    What is a typical timeline for NAb assay development and validation?

    The timeline varies based on the complexity of the therapeutic’s mechanism of action and the availability of key reagents. Development and validation are strategically planned to align with key milestones within the broader 18-24 month IND timeline for a given program.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

The Challenge: Biological Relevance and Drug Tolerance

The central challenge in NAb assay development is designing a method that is both biologically relevant and sufficiently tolerant to the presence of the therapeutic drug. High concentrations of circulating drug can mask the presence of NAbs by forming complexes, potentially leading to false-negative results and an underestimation of immunogenicity risk. An effective assay must be able to dissociate these complexes without damaging the NAbs themselves.

Furthermore, the assay must accurately reflect the therapeutic’s specific mechanism of action (MoA). An assay that measures binding inhibition may not capture the true functional consequence of a NAb response if the therapeutic works through a different pathway, such as antibody-dependent cellular cytotoxicity (ADCC). This necessitates a tailored approach to assay format selection to generate data that regulators will find meaningful for safety and efficacy assessment.

A Mechanistically-Driven Approach to NAb Assay Development

At Franklin Biolabs, we develop NAb assays grounded in the specific mechanism of action of your monoclonal antibody. Our approach ensures the assay format directly interrogates the functional consequence of an ADA response, providing clear, interpretable data for regulatory review.

  • Assay Format Selection: We guide the selection between cell-based and non-cell-based formats based on your therapeutic’s target, pathway, and risk profile.

  • Reagent Development: We manage the generation and characterization of key reagents, including positive control neutralizing antibodies, to ensure assay performance.

  • GxP Validation: All assays are validated in our >100,000 sq ft facility according to current FDA, EMA, and ICH guidelines, covering parameters such as specificity, sensitivity, precision, and drug tolerance.

Our process optimizations contribute to our clients’ success. Since 2019, programs that have engaged Franklin Biolabs for integrated bioanalytical support have achieved a 100% IND success rate. (The Franklin Biolabs brand was launched in 2024, building on this established operational history).

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

NAb Assay Platform Comparison

A multi-tiered testing strategy is often the most effective path for immunogenicity assessment. The choice between a cell-based or ligand-binding format depends on a risk-based evaluation of the therapeutic.

Feature Cell-Based NAb Assay Competitive Ligand-Binding Assay (LBA)
Biological Relevance High: Measures a direct physiological effect. Moderate: Infers neutralization via binding inhibition.
Complexity High: Requires cell line maintenance and culture. Low to Moderate: Standard plate-based format.
Throughput Lower Higher
Sensitivity Generally higher sensitivity for functional effects. Can be highly sensitive but may detect non-neutralizing ADAs.
Regulatory Preference Often preferred for high-risk biologics. Acceptable for many low-to-moderate risk programs.

By providing definitive data on functional immunogenicity, we help sponsors make faster, more informed decisions about candidate selection and clinical development strategy.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities